Roche and PTC’s Evrysdi (risdiplam) Receive the EC’s Approval as First and Only at Home Treatment For Spinal Muscular Atrophy

 Roche and PTC’s Evrysdi (risdiplam) Receive the EC’s Approval as First and Only at Home Treatment For Spinal Muscular Atrophy

Roche and PTC’s Evrysdi (risdiplam) Receive the EC’s Approval as First and Only at Home Treatment For Spinal Muscular Atrophy

Shots:

  • The approval is based on two studies i.e. FIREFISH and SUNFISH. The FIREFISH study involves assessing Evrysdi in infants aged 2-7mos. with symptomatic Type 1 SMA, and the SUNFISH study assesses Evrysdi in children & young adults with Type 2 or 3 SMA
  • Evrysdi demonstrated a favourable efficacy & safety profile, with the safety profile established across both trials. The EU approval is applicable to all 27 European Union member states, as well as Iceland, Norway, and Liechtenstein
  • The approval follows the positive CHMP’s recommendation, received in Feb’2021. Evrysdi has currently been approved in 38 countries and submitted in a further 33 countries

Click here to­ read full press release/ article | Ref: Roche | Image: Spain’s News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post